...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Additional Reports of Exempt Distribution

1) 2023-06-12 out of Alberta

Promissory Note, $534,646.00 CAN

700,000 warrants @ $1 expire 2028-06-12

 

2) 2023-06-26 out of USA

1,333.333 common shares @ $0.99 = $1,315,100.00 CAN

2 warrants per common share @ $0.99 expire 2028,06,26

 

Koo

Share
New Message
Please login to post a reply